Proteomics

Dataset Information

0

Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cells lines reveals conserved oncogenic pathways


ABSTRACT: Neuroblastoma is a neural crest-derived embryonal tumor or the postganglionic sympathetic nervous system. Neuroblastomas show heterogeneous biologic and clinical features and , whereas a subset may undergo spontaneous differentiation or regression with little or no therapy, the majorities are difficult to cure with current modalities. The origin of these tumours remains unknown in most cases, although a number of familial cases have been associated with mutations of the ALK gene. In this study we established both phosphoproteomic and gene expression profiles of ALK activity in neuroblastoma cells exposed to first and third generation ALK TKIs, to identify the underlying molecular mechanisms and identify relevant biomarkers, signaling networks, and new therapeutic targets.

INSTRUMENT(S): LTQ Orbitrap Elite, Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain, Epithelial Cell, Bone Marrow

DISEASE(S): Neuroblastoma

SUBMITTER: Vicky Yang  

LAB HEAD: Bengt Hallberg

PROVIDER: PXD011187 | Pride | 2018-11-27

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
041216_24489_HG_tdra_q.mzXML Mzxml
041216_24489_HG_tdra_q.raw Raw
041216_24490_HG_tdra_q.mzXML Mzxml
041216_24490_HG_tdra_q.raw Raw
041216_24491_HG_tdra_q.mzXML Mzxml
Items per page:
1 - 5 of 74
altmetric image

Publications

Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.

Van den Eynden Jimmy J   Umapathy Ganesh G   Ashouri Arghavan A   Cervantes-Madrid Diana D   Szydzik Joanna J   Ruuth Kristina K   Koster Jan J   Larsson Erik E   Guan Jikui J   Palmer Ruth H RH   Hallberg Bengt B  

Science signaling 20181120 557


Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor that is a clinical target of major interest in cancer. Mutations and rearrangements in <i>ALK</i> trigger the activation of the encoded receptor and its downstream signaling pathways. <i>ALK</i> mutations have been identified in both familial and sporadic neuroblastoma cases as well as in 30 to 40% of relapses, which makes ALK a bona fide target in neuroblastoma therapy. Tyrosine kinase inhibitors (TKIs) that target ALK are currently  ...[more]

Similar Datasets

2023-02-16 | PXD035100 | Pride
2018-09-01 | E-MTAB-6654 | biostudies-arrayexpress
2013-03-03 | E-MTAB-1367 | biostudies-arrayexpress
2012-07-05 | GSE35560 | GEO
2012-07-04 | E-GEOD-35560 | biostudies-arrayexpress
2024-06-14 | PXD051981 | Pride
2014-06-24 | E-GEOD-46583 | biostudies-arrayexpress
2014-06-24 | GSE46583 | GEO
2014-06-24 | GSE46584 | GEO
2014-06-24 | E-GEOD-46584 | biostudies-arrayexpress